The standard treatments for chronic lymphocytic leukemia (CLL) include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu). Tumor necrosis factor-related apoptosisinducing ligand (TRAIL) is a death receptor ligand that induces apoptosis preferentially in tumors. However, CLL cells seem to be resistant to TRAIL-induced apoptosis. The TRAIL apoptotic signaling pathway has also been implicated in genotoxin-induced apoptosis through upregulation of TRAIL death receptors DR4 and DR5. In the present study, we demonstrate that the treatment of primary CLL cells with CLB or Flu increases the mRNA, protein and cell surface expression levels of DR4 and DR5 in a dose-dependent manner. In contrast to CLL cells, drug treatment fails to increase significantly the expression of DR4 or DR5 in normal lymphocytes. CLL cells are, however, resistant to TRAIL-induced apoptosis compared to B-cell lines. In contrast, combinational treatment using CLB or Flu with TRAIL (100 ng/ml) gave a synergistic apoptotic response. Furthermore, TRAIL is readily detectable on the cell surface of CLL cells, but TRAIL expression fails to increase following drug treatment. Preventing TRAIL from interacting with DR4 and DR5 decreases CLB-induced apoptosis in CLL cells. A similar, but less marked effect is observed with Flu. These findings indicate the involvement of the TRAIL apoptotic pathway in the mechanism of action of chemotherapy, and this mechanism could be utilized to sensitize CLL cells to TRAIL-induced apoptosis.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is characterized by the accumulation of noncycling CD5 þ /CD19 þ lymphocytes in the peripheral blood, marrow, spleen and lymph nodes (Johnston, 1999) . This is a highly heterogeneous disease with one-third of patients never requiring treatment, whereas in others the disease progresses at a variable rate and can cause death within 1-2 years (Dighiero and Binet, 2000) . Death is usually related to infection caused by paresis of the immune system as a result of the accumulation of CLL cells. These long-lived cells are defective in apoptosis, possibly caused by increased levels of Bcl-2 (Gottardi et al., 1996; Johnston et al., 1997; Pepper et al., 1999) . Indeed, CLL cells die rapidly in vitro when Bcl-2 expression is downregulated by anti-sense Bcl-2 oligonucleotides (Pepper et al., 1999) . Alternatively, the reduction in apoptosis has been ascribed to the increased expression of the basic fibroblast growth factor, cyclin D2, nitric oxide synthase or p27 kip1 (Delmer et al., 1995; Menzel et al., 1996; Vrhovac et al., 1998; Zhao et al., 1998) . p53 mutations occur in 10% of patients and are associated with drug resistance and short survival (Dohner et al., 2000) .
The standard treatments for CLL include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu) (Johnston, 1999; Dighiero and Binet, 2000; Rai et al., 2000) . CLB alkylates DNA, RNA and cellular proteins leading to the activation of cysteine proteases called caspases, and subsequent induction of apoptosis (Begleiter et al., 1996) . Fludarabine is dephosphorylated in plasma to F-ara-A, and following cellular uptake is phosphorylated to F-ara-ATP, which produces DNA breaks, activation of caspase 9 and subsequent induction of apoptosis (Begleiter et al., 1995; Genini et al., 2000a, b) . Despite initial responses to therapy, relapse and eventual drug resistance usually occur in CLL patients. In addition, these treatments are lymphocytotoxic and myelotoxic, exacerbating the pre-existing immunosuppression and increasing the risk of autoimmune anemia and thrombocytopenia (Johnston, 1999; Dighiero and Binet, 2000; Rai et al., 2000) . Understanding the mechanism(s) involved in CLB-and Flu-induced apoptosis could lead to better targeted therapies for CLL.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) belongs to the TNF family of death receptor ligands (Ashkenazi and Dixit, 1999; Solary et al., 2000) . TRAIL binds to death receptor 4 (DR4) and death receptor 5 (DR5), which are expressed on the cell surface of many cancer cells, including leukemia cells Walczak et al., 1999; Gibson et al., 2000; Lincz et al., 2001; Mitsiades et al., 2001; Olsson et al., 2001; MacFarlane et al., 2002; Plasilova et al., 2002) . Ligation of DR4 or DR5 is accomplished by recruitment of an adaptor protein, Fasassociated death domain (FADD) , to the death receptor (Bodmer et al., 2000) . This adaptor protein constitutively binds to caspase 8 through the death effector domain, leading to caspase activation and apoptosis through two distinct pathways. The first pathway is caspase 8-mediated cleavage of caspase 3 and subsequent apoptosis. The second pathway is caspase 8-mediated cleavage of Bid, which upon cleavage translocates to the mitochondria thereby releasing cytochrome c, a process that requires Bax (Kim et al., 2001; Ravi and Bedi, 2002; Werner et al., 2002) . This release causes activation of caspase 9 and caspase 3, leading to apoptosis (Ashkenazi and Dixit, 1999) . TRAIL-induced apoptosis is negatively regulated by decoy receptors (DcR1 and DcR2) that bind TRAIL, but fail to recruit and activate caspase 8 (Ashkenazi and Dixit, 1999) . This effectively sequesters TRAIL away from its death receptors preventing apoptosis. The relative expression levels of these receptors will establish the sensitivity of cells to undergo TRAIL-induced apoptosis.
TRAIL has been proposed as a new treatment for cancer. Administration of TRAIL to SCID mice, inoculated with a variety of different human solid tumors, reduced the size of the tumors, and these could be eliminated entirely when TRAIL was combined with chemotherapy (Walczak et al., 1999) . TRAIL, however, is ineffective at inducing apoptosis in CLL cells possibly due to increased expression of the FLICE inhibitory protein (c-FLIP) (Irmler et al., 1997; Olsson et al., 2001) . Mechanisms for sensitizing CLL cells to TRAILinduced apoptosis in the context of standard chemotherapy are currently unknown.
Chemotherapeutic drugs used for the treatment of cancer activate many signaling pathways that contribute to cell death. Thus, DNA-damaging agents, such as doxorubicin and alkylating agents, have been shown to upregulate the expression of Fas ligand or Fas, and antagonistic antibodies to Fas or Fas ligand could decrease the apoptotic potential of these agents (Friesen et al., 1999; Fulda et al., 2000; Kolbus et al., 2000) . These results suggest that, at least in some cell types, the activity of antitumor agents may be related to upregulation of Fas ligand or Fas. In similar studies, we have demonstrated in epithelial cell lines that etoposide (ET) increases the expression of DR4 and DR5, and that blockage of death receptor activation reduces the activity of this drug (Gibson et al., 2000) . In addition, the antitumor effect of the retinoids in acute promyelocytic leukemia has recently been ascribed to upregulation of the expression of TRAIL (Altucci et al., 2001) .
Similar studies have been carried out to assess the role of the death receptors and their ligands for chemotherapy-induced apoptosis in CLL. Jones et al. (2001) have shown that CLB, Flu and irradiation increase procaspase 8 activation in CLL cells. However, this effect could not be related to upregulation of the Fas ligand or Fas expression. In the present study, we demonstrate that CLB and Flu increase DR4 and DR5 mRNA, protein and cell surface expression levels. Combined treatment of TRAIL with CLB or Flu results in a synergistic apoptotic response. Moreover, blockage of TRAIL death receptor activation reduces the procaspase 8 activation and apoptosis mediated by CLB, and to a lesser extent by Flu. In contrast, CLB and Flu do not affect DR4 or DR5 expressions in normal lymphocytes. These studies indicate the potential importance of the TRAIL apoptotic pathway for the antitumor effects of CLB and Flu in CLL.
Materials and methods

Patients and lymphocyte isolation
Peripheral blood samples were obtained from normal individuals and CLL patients following informed consent, in agreement with the Research Ethics Board at the University of Manitoba. The diagnosis of CLL was made by peripheral blood morphology and immunophenotyping, and the cells were CD19 þ , CD5 þ and CD23 þ (Johnston, 1999) . Mononuclear cells were isolated from the buffy coat using a FicollPaque density gradient, as we have previously described (Begleiter et al., 1995; Johnston et al., 1997) . The cell isolates were washed with ice-cold phosphate-buffered saline (PBS) (pH 7.4) and a second wash with ice-cold 10 mm Tris : 140 mm NH 4 Cl to lyse residual erythrocytes. When the peripheral blood lymphocyte counts were o30 Â 10 9 /l, contaminating monocytes were removed from the isolates using CD33 antibodies coupled to magnetic beads and T cells were removed by sheep red cell rosetting, as previously described (Begleiter et al., 1995; Johnston et al., 1997) . To minimize spontaneous apoptosis, lymphocytes were resuspended and cultured in serum-free hybridoma media (Hybridoma SFM) (Levesque et al., 2001) . Normal lymphocytes were isolated from healthy volunteers as described above, except that T cells were not removed by sheep red cell rosetting.
Isolation of his-tagged soluble TRAIL
Escherichia coli (BL21), containing the pET plasmid with 101-281a.a. soluble TRAIL cDNA, was grown overnight under selection (50 mg/ml ampicillin) and diluted 1 in 2. The bacteria were treated with 1 mm IPTG (isopropyl-1-thio-b-d-galactopyranoside) for 2 h and lysed in lysis buffer (10 mm Tris (pH 8.0), 100 mm NaCl, 0.1% NP-40, 5 mm immidizole and 2 mm phenylmethylsulfonyl fluoride (PMSF)). The lysate was sonicated 4 Â 15 s and centrifuged at 8000 g for 30 min. Nickel sepharose beads (500 ml) were added to the lysate and incubated for 2 h at 41C. The beads were then washed in wash buffer (10 mm Tris (pH 8.0), 100 mm NaCl, 0.1% NP-40 and 5 mm immidizole) three times and eluted with elution buffer (10 mm Tris (pH 8.0), 100 mm NaCl, 0.1% NP-40, 100-300 mm immidizole). The elutions were loaded on an sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomasie blue to visualize soluble TRAIL. The isolated TRAIL was used to treat cells in media where indicated. For the combinational treatment of TRAIL with CLB or Flu, TRAIL recombinant protein was purchased from Alexis Inc.
Cell culture and treatment conditions
Lymphocytes were cultured at 371C in a humidified, 5% CO 2 incubator at an initial density of 1 Â 10 6 cells/ml in hybridoma SFM culture media (Levesque et al., 2001) . WSU-CLL cells were also grown in RPMI 1640 supplemented with 100 U of penicillin, 100 mg streptomycin and 10% heat-deactivated fetal bovine serum. F-ara-A was used for these in vitro experiments, as Flu requires dephosphorylation to F-ara-A for activity, and this normally occurs rapidly in the plasma following clinical administration (Begleiter et al., 1995; Johnston et al., 1997) . For consistency, we will use the abbreviation Flu to denote Fara-A treatment. Cells were incubated with or without 10 mm CLB, 10 mm Flu, 100 mm ET or varied concentrations of TRAIL used alone or in combination with chemotherapy. Cells were also incubated with 100 ng/ml of DR4 : Fc alone or in combination with CLB or Flu.
MTT assay
Cell viability was assessed by the MTT (3-(4,5-dimethylthiazol2yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay, as we have previously described (Begleiter et al., 1996; Johnston et al., 1997) . Lymphocytes were incubated with varying concentrations of drug or TRAIL for 18 h at 371C in 5% CO 2 environment. Then a cell dilution was performed in quadruplicate in 96-well microtiter plates for each drug concentration including the nontreated control cells, and the cells incubated at 371C with 5% CO 2 for 78 h. A volume of 50 ml of MTT (1 mg/ml) in RPMI was added to each well, and plates were incubated at 371C for 2-6 h with 5% CO 2 . The microtiter plates were then spun for 10 min at 1500 r.p.m. and 150 ml of DMSO was added to each well to dissolve the dark blue crystals and the absorbance was read at 540 nm with a microplate reader.
Annexin V/7AAD staining
Cells (5 Â 10 6 ) were collected in 5 ml tubes, centrifuged and resuspended in 1 Â binding buffer (10 mm HEPES/NaOH (pH 7.4), 140 mm NaCl, 2.5 mm CaCl 2 ), supplemented with Annexin V-FITC (BD PharMingen, Mississauga, ON, USA) and 2.5 mg 7-amino actinomycin D (7-AAD) (Molecular Probes, Eugene, OR, USA). After 15 min of incubation at room temperature in the dark, an excess of 1 Â binding buffer was added to a final volume of 500 ml. Cells were then analysed with a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA, USA).
Acridine orange/ethidium bromide staining Cells were resuspended in 100 ml of medium by gentle mixing, and stained with a cocktail of acridine orange (100 mg/ml) and ethidium bromide (100 mg/ml) in PBS. A cell suspension was then applied onto a microscope slide, covered with a coverslip and the cells were viewed using a fluorescence microscope by using a fluorescein filter set to quantitate condensed DNA in apoptotic cells. Random fields were scored, and the percentage of apoptotic cells was determined from cells containing normal DNA to cells with condensed DNA. At least 200 cells were counted for each condition tested.
RNase protection assay
A riboQuant Multi-Probe RNase Protection Assay System (PharMingen, San Diego, CA, USA) was used as per the manufacturer's instructions. An hAPO3c probe set containing DNA templates for caspase 8, FASL, FAS, DcR1, DR3, DR5, DR4, TRAIL, TNFRp55, TRADD, RIP (receptor interacting protein), L32 and GAPDH (glyceraldehydes-3-phosphate dehydrogenase) was used for T7 RNA-polymerase direct synthesis of [a32-P]UTP-labeled antisense RNA probes. Alternatively, an hAPO2 was used to quantitate mRNA levels of BAX. The probes were hybridized with 20 mg of RNA isolated from the cells by using RNAzol B (Tel-Test, Inc.). Samples were then digested with RNase to remove singlestranded (nonhybridized) RNA. The remaining probes were resolved on denaturing 5% polyacrylamide gels. Quantitation was performed with a PhosphoImager (Molecular Dynamics).
Western blot analysis
Cells were lysed in NP-40 lysis buffer (50 mm HEPES (pH 7.25), 150 mm NaCl, 50 mm ZnCl 2 , 50 mm NaF, 2 mm EDTA, 1 mm sodium vanadate, 1.0% NP-40, 2 mm phenylmethylsulfonyl fluoride). Cell debris was removed by centrifugation and the protein concentration was determined by the Bradford assay. After SDS-PAGE, the proteins were transferred onto nitrocellulose membranes. The membranes were blocked with 5% milk in tris-buffered saline-Tween 20. Blots were performed as described previously (Gibson et al., 2002) . The blots were stripped in 10% SDS buffer and reprobed for bactin to normalize for protein loaded in each lane.
Analysis of cell surface antigens
Briefly, 5 Â 10 6 cells were collected in 5 ml tubes, centrifuged and resuspended in 100 ml of 1 Â PBS supplemented with 1% (w/v) bovine serum albumen (BSA) and 0.1% NaN 3 (sodium azide) (PBS-BSA-NaN 3 ). Cells were then labeled separately either with rabbit anti-human DR4 (H-130), goat anti-human DR5 (N-19), goat anti-human DcR1 (N-19) polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or mouse anti-human TRAIL/TNFSF10 monoclonal antibody (R&D Systems, Minneapolis, MN, USA). Cells were incubated for 1 h in the dark at 41C. After three washes with PBS-BSA-NaN 3 , cells labeled with anti-DR4 were incubated with goat anti-rabbit IgG FITC-conjugated, cells labeled with anti-TRAIL/TNFSF10 were incubated with goat anti-mouse IgG FITC-conjugated (Sigma, St Louis, MO, USA) and cells labeled with anti-DR4, anti-DR5 or anti-DcR1 were incubated with rabbit anti-goat IgG FITC-conjugated (KPL, Gaithersburg, MD, USA). After 1 h, in the dark, at 41C, cells were washed three times with PBS-BSA-NaN 3 , resupended in 2% paraformaldehyde and stored at 41C. Cells were then analysed by flow cytometry and the specific membrane receptor or TRAIL expressions measured by mean fluorescence intensity (MFI) with the specific antibody after subtracting the MFI obtained with the control (secondary antibody alone). MFI was determined as the mean of the distribution curve. Fold increase was calculated by the ratio of MFI in treated cells compared to the MFI in untreated cells. As a negative control, cells were incubated with rabbit IgG or goat IgG primary matched isotype. In addition, a blocking peptide (same as the antigen used to make the antibodies) was added to the cells to inhibit the antibodies from binding to the death receptors as a further control.
Fluorescent in situ hybrization (FISH)
CLL cells were cytospun onto slides. Slides were equilibrated in 2 Â SSC for 10 min at room temperature. A measure of 100 ml of a 100 mg/ml solution of RNase A (made in 2 Â SSC) was then placed on each sample and covered with a 24 Â 60 mm coverslip. The slides were placed in a 371C humidified chamber for 1 h. The slides were washed three times in 2 Â SSC, 5 min each, at room temperature with gentle shaking. The samples were then placed in an HCl solution containing pepsin for 10 min (50 mg/ml in 0.01 m HCl prewarmed to 371C) at 371C with gentle shaking. Following the pepsin treatment, the slides were washed twice in 1 Â PBS and once in 1 Â PBS/50 mm MgCl 2 , 5 min each with gentle shaking. The slides were then placed in freshly prepared 1% formaldehyde (made with 1 Â PBS/50 mm MgCl 2 ) for 10 min at room temperature with no shaking followed by a 5 min wash in 1 Â PBS, with gentle shaking. Dehydration of the samples then occurs by placing the slides in a series of ethanol washes, 70, 90 and 100%, 3 min each, and the slides were then allowed to fully air-dry. The samples were completely dried and were then prewarmed in a 701C oven for 5 min. The samples were then quickly placed in the denaturation solution (70% deionized formamide/2 Â SSC, pH 7.0) at 701C for exactly 2 min. The slides were then immediately transferred to a series of ice-cold ethanol incubations, 70, 90 and 100%, for 3 min each and allowed to air-dry fully. The probes used were CEP 10 spectrum green (hybridizes to the centrosome of chromosome 10) and LSI p53 spectrum orange (hybridizes to chromosome band 17q13.1, Vysis Inc.). The probes were denatured according to the manufacturer's instructions and 10 ml of each probe mixture was used for a total volume of 20 ml of hybridization mixture per sample. The hybridization mixture was covered by a 25 Â 25 mm coverslip and sealed with rubber cement. The slides were then allowed to hybridize with the probes at 371C in a dark humidified chamber for 16-18 h. The slides were washed the next day at 461C with gentle shaking (all solutions were prewarmed to this temperature prior to start of the washes) as follows: three times in 50% formamide/ 1 Â SSC, 10 min each, once in 2 Â SSC, 10 min and once in 2 Â SSC/1% NP-40, 5 min. The slides were then air-dried in the dark, and a commercial antifade (Vectashield) solution containing DAPI (two parts antifade/one part antifade containing DAPI) was placed on top of the sample and covered with a 24 Â 60 mm coverslip. The hybridization results were imaged using a Zeiss Axioplan II microscope with a Hamamatsu CCD camera (model C5985) and analysed with Metasystem Group Inc. software.
Results
CLB and Flu induce DR4 and DR5 mRNA, protein and cell surface expressions in primary CLL cells
In epithelial-derived cancers, we have shown that treatment with genotoxins induces DR4 and DR5 expressions (Gibson et al., 2000) . In the present study, we determined whether CLB or Flu induces DR4 and DR5 expression in primary CLL cells. CLL cells were treated with CLB (10 mm) or Flu (10 mm) for 72 h, and at different time points, mRNA was isolated and an RNase protection assay was carried out, as described in Materials and methods. The mRNA levels of both DR4 and DR5 increased following 18 h of treatment with either CLB or Flu, and the levels continued to increase during the 72 h of treatment (Figure 1 ). Similar to the epithelial cell lines, ET treatment also increased mRNA levels for DR4 and DR5 in primary CLL cells (Figure 1a ). Compared to untreated cells, the maximum mean-fold increases in DR4 and DR5 expressions with CLB treatment were 2.2 and 4.0, respectively (Figure 1b) . Following Flu treatment, the maximum mean-fold increases in DR4 and DR5 expressions were 3.2 and 5.0, respectively (Figure 1c) . Caspase 8 DcR1, DcR2 and TNF receptor mRNA levels did not significantly change over this time course, with either CLB or Flu (Figure 1a) .
Protein levels were determined for DR4 and DR5 following CLB treatment. DR4 protein levels were detectable in untreated cells; the levels increased following 48 h of treatment and increased further after 72 h of treatment. DR5 protein levels were not detectable in untreated cells, but upon longer exposure DR5 proteins were detected. Following CLB treatment, DR5 protein levels increased at 48 and 72 h (Figure 1d ). Similar results were found for Flu, but the extent of induction was less than that for CLB (data not shown).
The increase in cell surface expressions of DR4 and DR5 was determined by flow cytometry. Following 24 and 48 h treatment with CLB or Flu, the cell surface levels of DR4 and DR5 were increased, compared to untreated cells (Figure 2a ). DR4 upregulation occurred at 24 h and was still present at 48 h, while DR5 upregulation was not detected until 48 h (Figure 2 ). Both death receptors remained upregulated at 72 h (data not shown). To determine whether the degree of change in the expressions of DR4 and DR5 following drug treatment correlated with the extent of apoptosis, cells from five CLL patients were treated for 48 h with 10 mm CLB, 10 mm Flu or 100 mm ET. Following incubation, the change in MFI for DR4 and DR5 in drug-treated cells, compared to nontreated cells, was measured and the extent of apoptosis calculated for each drug by counting apoptotic cells. Cells from patient 5 did not show any change in DR4/DR5 cell membrane expression with CLB, Flu or ET. In the other four patients, following CLB treatment DR4 expression increased 2-6-fold while DR5 expression increased 2-12-fold (Table 1) . Similarly, Flu treatment increased DR4 expression 2-6-fold, while DR5 expression increased 2-19-fold, with the exception of patient 2 where DR4 and DR5 failed to increase (Table 1 ). The amount of apoptosis following treatment with the various chemotherapeutic drugs correlated with the level or induction of DR4 or DR5 in primary CLL cells (Table 2) . For example when etoposide induces DR4 and DR5 by 5.3-and 2.7-fold, respectively, the level of apoptosis was 65% after 48 h. This is in contrast to the same patient's CLL cells treated with CLB or Flu with DR4 and DR5 induction of less than twofold, with the level of apoptosis being only 18% for CLB and 20% for Flu after 48 h of treatment. This suggests that upregulation of TRAIL receptors sensitizes CLL cells to CLB-or Flu-induced apoptosis.
Finally, the level of cell surface expression of DR4 and DR5 following CLB or Flu treatment was determined in normal lymphocytes. CLB failed to induce either DR4 or DR5 significantly over a 48 h time course (Figure 3) . Flu was able to induce DR4 and DR5 expression in a subpopulation of normal lymphocytes, but failed to induce death receptor expression in the whole population (Figure 3) . Taken together, these data indicate that CLB and Flu treatments increase TRAIL death receptors in primary CLL cells, but are less effective at inducing the same receptors in normal lymphocytes.
DR4 and DR5 mRNA levels are increased by CLB or Flu in a dose-dependent manner Since CLB and Flu increased DR4 and DR5 expressions at relatively high concentrations (10 mm, Figure 1) , it was determined whether this increase was dependent on the concentration of drug. Primary CLL cells were incubated with a range of CLB or Flu concentrations (1.0-10 mm) for 48 h. The cells were then lysed and mRNA was isolated. An RNase protection assay was performed as described in Materials and methods (Figure 4a ). The mRNA levels for DR4 increased gradually to maximize at 2.2-fold following 8 mm CLB. The DR5 mRNA levels Role of TRAIL and its receptors in chemotherapy for CLL JB Johnston et al increased more markedly, being increased 2.2-fold following 1 mm CLB and 4.5-fold following 10 mm CLB treatment (Figure 4b ). Following Flu treatment, DR4 mRNA levels increased 3.4-fold with 10 mm Flu and DR5 mRNA levels increased sixfold (Figure 4c ). These results indicate that CLB or Flu increases mRNA levels of DR4 and DR5 in a dose-dependent manner, with the changes being most marked for DR5. As previously observed, Fas mRNA levels increased in a dosedependent manner for both CLB and Flu (Figure 4a ) (Jones et al., 2001) .
Primary CLL cells are resistant to TRAIL-induced apoptosis but give a synergistic apoptotic response in combination with CLB or Flu
As chemotherapy induces TRAIL death receptor expression in CLL cells, and blockage of TRAIL death receptor activation reduces chemotherapy-induced apoptosis, we evaluated whether TRAIL alone could induce apoptosis in CLL cells. The CLL cells from 16 patients were incubated with TRAIL over a range of concentrations and an MTT assay was performed as described in Materials and methods. The MTT assay was used since this is a good predictive assay for clinical response (Johnston, 1999) . A total of 12 CLL patient samples were sensitive to TRAIL with the IC 50 concentration varying from 2.5 to 6.8 mg/ml (median, 3.75 mg/ml), while the cells from four patients demonstrated an IC 50 greater than 8 mg/ml. Normal lymphocytes were also resistant to TRAIL and had an IC 50 of 420 mg/ml (Table 2) . When primary CLL cells were compared to normal lymphocytes over a range of TRAIL concentrations, TRAIL induced apoptosis in CLL cells at concentrations that did not induce cell death in normal lymphocytes (data not shown).
Although primary CLL cells were more sensitive to TRAIL than normal lymphocytes, they were less sensitive than the B-cell line WSU-CLL, where the IC 50 was 0.9 mg/ml and markedly less sensitive than Jurkat and BJAB cells (data not shown). This indicates that CLL cells are relatively resistant to TRAIL-induced apoptosis.
Since relatively high levels of TRAIL are needed to induce apoptosis in CLL cells and CLB or Flu treatment increases DR4 and DR5 expression, CLL cells were The fold increase in DR4 and DR5 expression following drug treatment was determined by the ratio of MFI in drug-treated cells versus MFI of untreated cells as measured by flow cytometry. Cells were treated with 10 mm CLB, 10 mm Flu and 100 mm ET for 48 h. Cell death was measured at 48 h by Annexin V/7AAD staining using flow cytometry as described in the Materials and methods section treated with sublethal doses of CLB (1 mm) or Flu (0.5 mm) in combination with a concentration of TRAIL (100 ng/ml) that significantly induces apoptosis in B-cell lines. Initially, combined treatment of CLB or Flu with TRAIL failed to give a synergistic apoptotic response when the apoptotic stimuli were added together (data not shown). This was not unexpected since CLB or Flu failed to increase TRAIL receptors until 48 h after treatment (Figure 1 ). To determine if TRAIL can give a synergistic apoptotic response when its receptors are upregulated, primary CLL cells were treated with CLB or Flu for 48 h followed by TRAIL treatment for 24 h. This resulted in a synergistic apoptotic response ( Figure 5 ). The synergistic apoptotic response was also observed in an additional four patients. To confirm if TRAIL could be an effective treatment in combination with chemotherapy, the B-cell line WSU-CLL was treated with CLB (IC 20 concentration) in combination with TRAIL over a range of concentrations. Cell viability was consistently lower with combinations of CLB and TRAIL than the predicted additive effects of the two apoptotic agents (Figure 5c ). It is important to note that DR4 and DR5 expression levels increase after only 8 h of treatment with CLB or Flu in WSU-CLL cells compared with 48 h in CLL cells. This suggests that primary CLL cells are sensitized to TRAIL-induced apoptosis following treatment with CLB or Flu. Besides the importance of synergy to lower the concentration of TRAIL required to induce apoptosis, the rate of clearance of TRAIL in patients, and thus the optimum mode of administration of this agent, could affect the ability of TRAIL to induce apoptosis. To determine whether the duration of TRAIL exposure influences the extent of apoptosis, we evaluated the effect of different TRAIL concentrations (0.1-1 mg/ml) and exposure times (15-120 min) against WSU-CLL cells since these cells are sensitive to TRAIL-induced apoptosis. Using a 0.1 mg/ml concentration of TRAIL, WSU-CLL cells failed to undergo significant apoptosis (410%) at all exposure times tested. At 0.5 mg/ml TRAIL, cells underwent apoptosis following 45 min of exposure and the amount of apoptosis increased slowly to approximately 25% at 120 min. At 1.0 mg/ml TRAIL, approximately 30% of cells were undergoing apoptosis at 15 min and this increased to 55% at 120 min (Figure 5d ). These results indicate that the time of exposure and concentration of TRAIL will determine the extent of apoptosis.
TRAIL is expressed on the cell surface of CLL cells and blockage of TRAIL binding to its receptors contributes to CLB-induced apoptosis CLL cells were treated with CLB (10 mm) or Flu (10 mm) for 24 and 48 h. The cells were then incubated with antibodies against TRAIL and analysed by flow cytometry. TRAIL was detectable on the cell surface, but its expressions did not increase following treatment with either CLB or Flu (Figure 6a ). These findings were reproduced using cells from two further patients (data not presented) and also confirmed by detection of mRNA for TRAIL, which indicated that mRNA levels remained constant during CLB or Flu treatment (data not shown).
Since TRAIL is expressed on the cell surface of primary CLL cells and CLB increases both DR4 and DR5 expression to the extent that it correlates with drug sensitivity, we determined whether blockage of TRAIL death receptor activation inhibits CLB-induced apoptosis in these cells. Cells were incubated with a fusion protein consisting of the extracellular domain of DR4 and the Fc domain found in human antibodies (Figure 6b ). Treatment with DR4 : Fc alone failed to induce apoptosis. As a negative control, unrelated TNFR : Fc protein was added to CLL cells alone or in combination with CLB. The amount of CLB-induced apoptosis remained unchanged in the presence of TNFR : Fc (Figure 6b ). When cells from six patients were incubated with DR4 : Fc along with CLB, the mean protection provided by DR4 : Fc was 36% (range 21-65%) (Table 3) . DR4 : Fc provided less protection with Flu treatment, reducing mean apoptosis by 18% (range 0-49%) (Table 3 ). This protection from DR4 : Fc was not due to nonspecific protective effects of the Fc fragment since DR4 : Fc failed to protect CLL cells from spontaneous apoptosis (data not shown). Since death receptor stimulation leads to procaspase 8 cleavage and subsequent activation (Ashkenazi and Dixit, 1999) , we determined if DR4 : Fc inhibited CLBinduced procaspase 8 activation. Primary CLL cells were incubated with CLB for 72 h, and the cells were then lysed and Western blotted for caspase 8. As observed by others, after 72 h of CLB treatment, procaspase 8 was cleaved into its active form (Figure 6c) (Jones et al., 2001 ). In addition, DR4 was immunoprecipitated and Western blotted for FADD. After CLB treatment, the amount of DR4 and FADD bound to DR4 increased, indicating that the death receptor was activated. Cells were then incubated for 72 h with DR4 : Fc in the presence or absence of CLB. Pro-caspase 8 was present in untreated cells and in cells incubated with DR4 : Fc alone; however, with CLB treatment, procaspase 8 expression was decreased indicating cleavage to its active form. When DR4 : Fc and CLB were present, procaspase 8 cleavage was reduced ( Figure 6c ). As a negative control, the cells were incubated with TNFR : Fc protein. These results indicate that CLB cytotoxicity in primary CLL cells is partially mediated through activation of the TRAIL death receptors.
Primary CLL cells with p53 mutation fail to increase TRAIL receptors following CLB or Flu treatment
In all, 10% of CLL patients have a mutation in p53 that correlates with poor prognosis (Johnston, 1999) . DR5 upregulation by genotoxins is regulated by p53 in lung carcinoma cell lines (Takimoto and El-Deiry, 2000) . We determined if a mutation of p53 in CLL cells affects CLB-or Flu-induced upregulation of DR4 and DR5. To determine if there is a defect in the p53 pathway, CLL cells were treated with CLB or Flu and the level of induction of BAX mRNA (a p53-regulated gene; Schuler and Green, 2001 ) was determined. Following either CLB or Flu treatment, two CLL patients showed significant induction of mRNA for BAX but the third patient cells failed to increase BAX mRNA (Figure 7a ). This indicates that the third patient might have a mutation in p53. To confirm this, FISH analysis was used to detect deletion in chromosome 17q13 (site of the p53 gene), which is associated with a mutation in the other p53 allele (Lens et al., 1997; Sankar et al., 1998) . Indeed, CLL cells from a patient that failed to induce BAX mRNA also have a deletion in chromosome 17q13 as denoted by only a single signal from the p53 probe in the nucleus of CLL cells (Figure 7b) . Furthermore, 80%
Figure 5 CLB or Flu in combination with TRAIL gives a synergistic apoptotic response. (a) Primary CLL cells were isolated from patients and treated with (i) CLB (1 mm) or (ii) Flu (0.5 mm) for 48 h. The cells were also untreated (control). After 48 h, TRAIL (100 ng/ml) was added to the cells for an additional 24 h where indicated. At 72 h, the cells were analysed for the amount of apoptosis using acridine orange staining. Similar results were found with Annexin V staining. (b) The B-cell line WSU-CLL was treated with an IC 20 concentration of CLB and a range of TRAIL concentrations as indicated. The cells were incubated for 24 h and the amount of apoptosis determined as described above. (c) WSU-CLL cells were exposed to a range of concentrations for TRAIL (0.1-1.0 mg/ml) with increasing exposure times (15-120 min). After exposure to TRAIL, the cells were washed and incubated for 48 h. The amount of cell death was determined by acridine orange staining, as described in Materials and methods of these cells contain this deletion (data not shown). In contrast, the first patient who had induction of BAX expression following drug treatment showed two p53 probe signals in the nucleus of CLL cells suggesting the presence of wild-type p53 (Figure 7b) . The CLL cells from patient #2 also had wild-type p53 present (data not shown). A probe specific for the centromere in chromosome 10 was used as a positive control (green signal).
These same patients were then tested for upregulation of DR4 and DR5 following CLB or Flu treatment. In Figure 7c , only CLL cells from patient #1 with wild-type p53 showed an increase in mRNA for DR4 and DR5 following drug treatment over a dose range, while CLL cells from patient #3 with a p53 mutation failed to increase either DR4 or DR5. This was further confirmed by flow cytometry (data not shown). Similar results were The amount of cell death was determined by acridine orange assay as described in Materials and methods. As a negative control, cells were also treated with TNFR : Fc alone, CLB alone or in combination over a 72 h time course. (b) (i) Primary CLL cells untreated or treated with CLB for a 72 h time course. They were lysed and Western blotted for procaspase 8. The blot was then stripped and reprobed for b-actin. In addition, the cell lysate was immunoprecipitated for DR4 and Western blotted for FADD and DR4 after 48 h CLB treatment. (ii) Primary CLL cells were also untreated or treated as in (a) and incubated for 72 h. The cells were lysed and Western blotted for procaspase 8 and stripped and reprobed for b-actin also found in another patient with a p53 mutation. Treatment of CLL cells with p53 mutation also failed to give a synergistic response between CLB and TRAIL (data not shown). This indicates that p53 might play a role in upregulation of TRAIL death receptors in CLL following treatment with CLB or Flu.
Discussion
TRAIL appears to be a promising new treatment for leukemia, as it can induce apoptosis in tumor cells with relative sparing of normal cells. Indeed, TRAIL can induce apoptosis in acute lymphoid and myeloid leukemias, multiple myeloma, acute promyelocytic leukemia and in myelodysplastic syndromes Walczak et al., 1999; Gibson et al., 2000; Wen et al., 2000; Di Pietro et al., 2001; Lincz et al., 2001; Mitsiades et al., 2001; Olsson et al., 2001; MacFarlane et al., 2002; Plasilova et al., 2002) . Previous studies have demonstrated that primary CLL cells are considerably more resistant to TRAIL than leukemia cell lines using apoptotic assays (Olsson et al., 2001; MacFarlane et al., 2002) . In the present study, we used the MTT assay to assess cell death since this assay has been demonstrated to correlate with clinical outcome using CLB or Flu. Not unexpectedly, the B-cell line WSU-CLL was more sensitive than primary CLL cells to TRAIL. However, there was a wide range of TRAIL sensitivity between CLL cells isolated from different patients. It is unclear why CLL cells vary in their sensitivities to TRAIL, but it is unrelated to the cell membrane expressions of DR4 or DR5. The levels of Bax and Bcl-2 vary in CLL cells (Johnston et al., 1997) , but whether these influence TRAIL sensitivities is presently unknown. An antiapoptotic protein that might affect TRAIL-induced apoptosis is FLIP (Olsson et al., 2001; MacFarlane et al., 2002) . FLIP binds to procaspase 8 preventing its cleavage following death receptor activation (Irmler et al., 1997) . Resistance of CLL cells to TRAIL has been ascribed to an increase in FLIP expression. Reducing the levels of FLIP with actinomycin D has been shown to increase the sensitivity of CLL cells to TRAIL (Olsson et al., 2001) . Similarly, the sensitivity of multiple myeloma cell lines has recently been related to increased levels of FLIP or reduced activity of procaspase 8, and sensitivity to TRAIL has been restored through forced expression of procaspase 8 or using antisense oligonucleotides against FLIP (Mitsiades et al., 2002) . Furthermore, treating cells with proteasome inhibitors also sensitizes leukemia cells to TRAIL-induced apoptosis presumably by inhibiting the transcription factor NF-kB (Kim et al., 2002; Sayers et al., 2003) . Herein we have demonstrated that a combination of sublethal doses of CLB or Flu (currently used to treat CLL) with TRAIL gives a synergistic apoptotic response in primary CLL cells. This suggests that CLB or Flu might be effective at sensitizing primary CLL cells to TRAIL-induced apoptosis.
It has previously been demonstrated that antitumor agents, such as ET, doxorubicin, Ara-C, 5-FU and cisplatinum, or irradiation can upregulate the expressions of DR4 and DR5 in acute leukemia, multiple myeloma and solid tumor cell lines Gibson et al., 2000; Wen et al., 2000; Di Pietro et al., 2001; Mitsiades et al., 2001) . In the present study, we have determined whether a similar phenomenon can occur in primary CLL cells, and have shown in these cells that treatment with CLB or Flu increases the expressions of DR4 and DR5 at the mRNA, protein and cell membrane levels. Interestingly, Fas mRNA levels are also significantly increased with both Flu and CLB, although previous studies have shown that the protein levels of this death receptor are not influenced by these drugs (Jones et al., 2001) . In contrast, these drugs do not significantly affect DR4 or DR5 expressions in normal lymphocytes. There was, however, a small subpopulation of normal lymphocytes that increases DR4 expression, which could be sensitive to TRAIL treatment. Doses of Flu and CLB that are clinically achievable (1 mm) showed significant induction of DR4 and DR5. This induction of DR4 and DR5 also correlated with drug sensitivity and the ability of TRAIL to synergize with CLB or Flu to induce apoptosis. Furthermore, blockage of TRAIL apoptotic pathways reduced CLBinduced apoptosis in primary CLL cells similar to the reduction of etopsoside-induced apoptosis in epithelial cell lines by blocking the TRAIL-apoptotic pathway. Thus it is likely that upregulation of DR4 and DR5 sensitizes CLL cells to drug-induced apoptosis. Zhao et al. (1998) have previously shown that primary CLL cells produce TRAIL. CLL cells were found to kill TRAIL-sensitive Jurkat cells in a dose-dependent manner, and the apoptosis could be partially or completely inhibited by TRAIL antibody in three of six cases (Zhao et al., 1998) . We have confirmed in the present study that CLL cells express TRAIL on the cell surface, but the levels are not increased by either CLB or Flu. The situation is thus unlike acute promyelocytic leukemia, where the antitumor activity of the retinoids has been related to upregulation of TRAIL expression, which may induce cell death through a paracrine mechanism (Altucci et al., 2001) . Furthermore, DcR1 and DcR2 mRNAs were increased (Jones et al., 2001) . In a previous study, we demonstrated that the TRAIL apoptotic pathway is required for etoposide to induce apoptosis in epithelial cell lines (Gibson et al., 2000) . Using a similar approach, in the present study we showed that DR4 : Fc reduced the apoptotic activities of CLB and Flu against primary CLL cells by 40 and 20%, respectively. In addition, the cleavage of procaspase 8 by CLB was reduced by DR4 : Fc. These results strongly suggest that part of the antitumor activity of CLB and Flu is related to upregulation of DR4 and DR5 expression on the cell surface, which sensitizes the cells to TRAIL. The difference in protection by DR4 : Fc against Flu-and CLB-induced apoptosis may be related to differences in the mechanisms of these two drugs. CLB alkylates DNA and is believed to trigger apoptosis by activating the mitochondrial pathway through upregulation of p53 and alterations in the expressions of Bax and Bcl-2 (Schuler and Green, 2001) . Similarly, TRAIL also acts through the mitochondrial apoptotic pathway, and the combination may thus increase CLBinduced apoptosis (Ashkenazi and Dixit, 1999) . Thus, although CLB may initiate apoptosis, the subsequent upregulation of DR4 and DR5 with activation of the TRAIL apoptotic pathway will enhance cell kill. In contrast, although F-ara-ATP, the active intracellular metabolite of Flu, can activate mitochondrial apoptosis by inducing DNA strand breaks, F-ara-ATP can bypass the mitochondria for caspase activation. To do this, Fara-ATP replaces dATP in the apotosome and interacts with cytochrome c and APAF-1 (apoptosis proteinactivating factor-1) for caspase 9 activation (Genini Figure 7 Expression of DR4 and DR5 following CLB or Flu treatment in p53 mutant CLL cells. (a) CLL cells were treated with CLB (10 mm) or Flu (10 mm) for the times indicated above. The cells were then lysed and RNA isolated as described in the Materials and methods section. An RNase protection assay was performed using a probe that detects BAX mRNA as described in the Materials and methods section. Fold increase in BAX mRNA was determined relative to untreated cells. (b) FISH was performed on CLL cells with an ISI p53 probe (red signal) that hybridizes to chromosome 17q13.1 and with a control CEP10 probe (green signal) that hybridizes to the centromere of chromosome 10. DNA was visualized with Hoescht stain. Loss of p53 signal was observed in 80% of CLL cells from patient #3. (c) CLL cells were incubated with a range of concentrations of CLB or Flu for 48 h and mRNA was then isolated. The amount of mRNA for DR4 and DR5 was determined by RNase protection assay as described above et al., 2000a). Nevertheless, activation of the TRAIL apoptotic pathway may have a potentiating effect on drug cytotoxicity without TRAIL treatment.
The DR4 and DR5 mRNA expression levels were found to be increased by CLB and Flu in a dosedependent manner, indicating that the upregulation of the death receptors was controlled by transcription factors. Etoposide-or irradiation-mediated upregulation of DR4 and DR5 expressions in cell lines has been shown to involve the activation of NF-kB (Gibson et al., 2000; Ravi et al., 2001) . Furthermore, p53 activation has been shown to increase DR5 in lung cancer cell lines, while AP-1 (activator protein 1) activation appears to be involved in DR4 upregulation (Takimoto and El-Deiry, 2000; Wu et al., 2000; Guan et al., 2002) . It is unclear if these factors are involved in the upregulation of DR4 and DR5 in primary CLL cells with drug treatment. We have determined in at least two patients that a p53 mutation results in no significant increase in TRAIL death receptor expression. This suggests that p53 may be important for upregulation of these receptors. Evaluating the roles of the transcription factors involved in CLB and Flu induction of DR4 and DR5 expressions in primary CLL cells might provide an insight into which patients would benefit from TRAIL treatment and those for which this treatment will be ineffective. This will be the focus of ongoing investigations.
In summary, CLB or Flu increases the expression of TRAIL receptors and sensitizes CLL cells to TRAILinduced apoptosis. Furthermore, upregulation of TRAIL death receptors contributes to CLB cytotoxicity. This could provide an approach to treat CLL or other leukemias that are resistant to TRAIL-induced apoptosis with TRAIL in combination with standard chemotherapy. Clearly, clinical trials are required to determine the maximum tolerated dose of TRAIL in humans and the pharmacokinetics of this protein alone and in combination with standard chemotherapeutic drugs.
